Henry Schein (NASDAQ:HSIC) Stock Rating Upgraded by Wall Street Zen

Henry Schein (NASDAQ:HSIC) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

Several other research analysts also recently commented on HSIC. Stifel Nicolaus reaffirmed a “hold” rating and issued a $75.00 price objective (down previously from $80.00) on shares of Henry Schein in a research note on Friday, July 25th. Evercore ISI raised Henry Schein from an “in-line” rating to an “outperform” rating and set a $83.00 price objective on the stock in a research note on Tuesday, August 26th. Barrington Research reiterated an “outperform” rating and set a $78.00 target price on shares of Henry Schein in a research report on Tuesday, September 23rd. Leerink Partners set a $75.00 target price on Henry Schein in a research report on Monday, July 14th. Finally, Baird R W cut Henry Schein from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 14th. Five analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $76.67.

Henry Schein Stock Up 1.5%

HSIC stock opened at $67.03 on Friday. Henry Schein has a fifty-two week low of $60.56 and a fifty-two week high of $82.49. The business’s 50-day moving average is $67.93 and its two-hundred day moving average is $68.98. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.78 and a current ratio of 1.41. The company has a market cap of $8.13 billion, a price-to-earnings ratio of 21.62, a P/E/G ratio of 2.21 and a beta of 0.81.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, August 5th. The company reported $1.10 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.09). Henry Schein had a net margin of 3.05% and a return on equity of 14.36%. The firm had revenue of $3.24 billion during the quarter, compared to the consensus estimate of $3.22 billion. During the same period in the prior year, the company posted $1.23 EPS. The firm’s revenue was up 3.3% compared to the same quarter last year. Henry Schein has set its FY 2025 guidance at 4.800-4.940 EPS. As a group, analysts forecast that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Investors Weigh In On Henry Schein

A number of institutional investors and hedge funds have recently modified their holdings of the business. Central Pacific Bank Trust Division lifted its stake in shares of Henry Schein by 2.7% during the 3rd quarter. Central Pacific Bank Trust Division now owns 11,300 shares of the company’s stock worth $750,000 after acquiring an additional 300 shares during the last quarter. Squarepoint Ops LLC raised its position in Henry Schein by 724.4% during the 2nd quarter. Squarepoint Ops LLC now owns 46,841 shares of the company’s stock valued at $3,422,000 after purchasing an additional 41,159 shares in the last quarter. Thompson Davis & CO. Inc. bought a new stake in Henry Schein during the 2nd quarter valued at $1,262,000. Westwood Holdings Group Inc. bought a new stake in Henry Schein during the 2nd quarter valued at $20,631,000. Finally, CYBER HORNET ETFs LLC bought a new stake in Henry Schein during the 2nd quarter valued at $25,000. 96.62% of the stock is owned by institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.